303 related articles for article (PubMed ID: 33086187)
21. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.
Raviprakash K; Wang D; Ewing D; Holman DH; Block K; Woraratanadharm J; Chen L; Hayes C; Dong JY; Porter K
J Virol; 2008 Jul; 82(14):6927-34. PubMed ID: 18480438
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
Leo YS; Wilder-Smith A; Archuleta S; Shek LP; Chong CY; Leong HN; Low CY; Oh ML; Bouckenooghe A; Wartel TA; Crevat D
Hum Vaccin Immunother; 2012 Sep; 8(9):1259-71. PubMed ID: 22894958
[TBL] [Abstract][Full Text] [Related]
23. Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Yang Y; Meng Y; Halloran ME; Longini IM
Clin Infect Dis; 2018 Jan; 66(2):178-184. PubMed ID: 29020332
[TBL] [Abstract][Full Text] [Related]
24. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
[TBL] [Abstract][Full Text] [Related]
25. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil.
Dayan GH; Garbes P; Noriega F; Izoton de Sadovsky AD; Rodrigues PM; Giuberti C; Dietze R
Am J Trop Med Hyg; 2013 Dec; 89(6):1058-1065. PubMed ID: 24189367
[TBL] [Abstract][Full Text] [Related]
27. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
28. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Dayan GH; Thakur M; Boaz M; Johnson C
Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
[TBL] [Abstract][Full Text] [Related]
29. Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.
Ravel G; Mantel N; Silvano J; Rogue A; Guy B; Jackson N; Burdin N
Vaccine; 2017 Oct; 35(43):5918-5923. PubMed ID: 28882438
[TBL] [Abstract][Full Text] [Related]
30. Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.
Torresi J; Richmond PC; Heron LG; Qiao M; Marjason J; Starr-Spires L; van der Vliet D; Jin J; Wartel TA; Bouckenooghe A
J Infect Dis; 2017 Oct; 216(7):834-841. PubMed ID: 28968794
[TBL] [Abstract][Full Text] [Related]
31. Current progress in dengue vaccines.
Wan SW; Lin CF; Wang S; Chen YH; Yeh TM; Liu HS; Anderson R; Lin YS
J Biomed Sci; 2013 Jun; 20(1):37. PubMed ID: 23758699
[TBL] [Abstract][Full Text] [Related]
32. Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.
Henein S; Swanstrom J; Byers AM; Moser JM; Shaik SF; Bonaparte M; Jackson N; Guy B; Baric R; de Silva AM
J Infect Dis; 2017 Feb; 215(3):351-358. PubMed ID: 27932620
[TBL] [Abstract][Full Text] [Related]
33. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
34. Dengue vaccine candidates in development.
Durbin AP; Whitehead SS
Curr Top Microbiol Immunol; 2010; 338():129-43. PubMed ID: 19802583
[TBL] [Abstract][Full Text] [Related]
35. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
[TBL] [Abstract][Full Text] [Related]
36. Targets and strategies for vaccine development against dengue viruses.
Wang WH; Urbina AN; Lin CY; Yang ZS; Assavalapsakul W; Thitithanyanont A; Lu PL; Chen YH; Wang SF
Biomed Pharmacother; 2021 Dec; 144():112304. PubMed ID: 34634560
[TBL] [Abstract][Full Text] [Related]
37. Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.
George SL; Wong MA; Dube TJ; Boroughs KL; Stovall JL; Luy BE; Haller AA; Osorio JE; Eggemeyer LM; Irby-Moore S; Frey SE; Huang CY; Stinchcomb DT
J Infect Dis; 2015 Oct; 212(7):1032-41. PubMed ID: 25791116
[TBL] [Abstract][Full Text] [Related]
38. Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination.
Vigne C; Dupuy M; Richetin A; Guy B; Jackson N; Bonaparte M; Hu B; Saville M; Chansinghakul D; Noriega F; Plennevaux E
Hum Vaccin Immunother; 2017 Sep; 13(9):2004-2016. PubMed ID: 28598256
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
40. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
Pitisuttithum P; Bouckenooghe A
Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
